Concord Biotech Ltd. (CONCORDBIO) AI Stock Analysis

• Market Cap: ₹152.42B
• Dividend Yield: 0.76%
• Average Volume (3M): 12.81K
• Price to Earnings (P/E): 42.8
• Beta (1Y): 0.97
• Revenue Growth: 14.49%
• EPS Growth: 13.70%
• Country: IN
• Employees: 1,377
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 4.20
• Shares Outstanding: 104,616,200
• 10 Day Avg. Volume: 31,605
• 30 Day Avg. Volume: 12,808
• PEG Ratio: 2.26
• Price to Book (P/B): 9.59
• Price to Sales (P/S): 14.49
• P/FCF Ratio: 127.64
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹1,825.00
• Price Target Upside: 29.20% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 61 Neutral
• Price Target: ₹1,539.00 ▲(8.95% Upside)

Concord Biotech Ltd. has a strong financial foundation with excellent revenue and profit growth, supported by a robust balance sheet. However, the technical indicators suggest bearish momentum, and the valuation appears high, which could limit upside potential. The lack of earnings call data and corporate events means these factors do not influence the score.

Concord Biotech Ltd. Business Overview & Revenue Model

Company Description

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. It provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. The company also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment; mupirocin, mupirocin calcium, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, and micafungin sodium for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. In addition, it provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.

How the Company Makes Money

Concord Biotech generates revenue primarily through the sale of its biopharmaceutical products, including biosimilars and APIs. The company engages in both direct sales and partnerships with other pharmaceutical companies, which may involve licensing agreements and co-development arrangements. Significant revenue streams include the commercialization of biosimilars in various markets, where they compete with original biologics, as well as supplying APIs to other pharmaceutical manufacturers. Additionally, strategic collaborations with research institutions and industry partners for the development of new products contribute to its earnings, enhancing its market presence and expanding its product portfolio.

Concord Biotech Ltd. Financial Statement Overview

Summary

Concord Biotech Ltd. exhibits strong financial health with robust revenue and profit growth. The balance sheet shows low leverage and high equity, indicating financial stability. Cash flow management is generally effective, though variability in free cash flow growth suggests a need for careful capital planning.

Income Statement

Concord Biotech Ltd. has demonstrated strong revenue growth over the years, with a notable increase from 2020 to 2025. Gross profit margin and net profit margin are robust, reflecting efficient cost management and operational success. The EBIT and EBITDA margins indicate solid profitability, with consistent growth. However, the gross profit margin has slightly decreased, signaling potential cost pressures that need monitoring.

Balance Sheet

The balance sheet is strong, with a low debt-to-equity ratio, indicating minimal financial leverage and risk. The equity ratio is high, showing significant equity financing. Return on equity is commendable, highlighting effective use of shareholder funds. Overall, the company shows financial stability and prudent financial management.

Cash Flow

Operating cash flow is consistently positive and growing, underscoring effective cash management. Free cash flow also shows positive trends, although growth has fluctuated across the years. The operating cash flow to net income ratio is favorable, indicating good cash conversion from profits. However, the free cash flow growth rate has been inconsistent, presenting potential challenges in sustaining capital investments.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	11.88B	12.00B	10.17B	8.53B	7.13B	6.17B
Gross Profit	7.87B	7.68B	6.67B	6.61B	5.41B	5.00B
EBITDA	4.89B	5.13B	4.39B	3.53B	2.78B	3.29B
Net Income	3.56B	3.72B	3.08B	2.40B	1.75B	2.35B
Balance Sheet
Total Assets	0.00	20.34B	17.01B	15.14B	13.13B	11.83B
Cash, Cash Equivalents and Short-Term Investments	3.18B	3.18B	2.86B	1.81B	1.62B	2.01B
Total Debt	0.00	29.69M	97.38M	315.47M	624.93M	892.83M
Total Liabilities	-18.13B	2.22B	1.74B	2.24B	2.10B	1.83B
Stockholders Equity	18.13B	18.13B	15.27B	12.90B	11.03B	9.99B
Cash Flow
Free Cash Flow	0.00	1.36B	1.80B	1.01B	519.70M	-373.59M
Operating Cash Flow	0.00	2.47B	2.65B	2.46B	2.07B	1.67B
Investing Cash Flow	0.00	-1.63B	-1.55B	-1.58B	-1.12B	-1.95B
Financing Cash Flow	0.00	-986.67M	-992.15M	-852.19M	-1.00B	311.24M

Concord Biotech Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1412.55
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:CONCORDBIO, the sentiment is Negative. The current price of 1412.55 is below the 20-day moving average (MA) of 1501.77, below the 50-day MA of 1586.29, and below the 200-day MA of 1723.24, indicating a bearish trend. The MACD of -46.07 indicates Positive momentum. The RSI at 32.24 is Neutral, neither overbought nor oversold. The STOCH value of 23.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:CONCORDBIO.

Concord Biotech Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SYNGENE	71 Outperform	₹260.38B	51.13	―	0.19%	8.57%	-2.93%
JUBLINGREA	63 Neutral	₹109.82B	37.76	―	0.75%	3.80%	64.94%
CONCORDBIO	61 Neutral	₹152.42B	42.80	―	0.76%	14.49%	13.70%
BLUEJET	61 Neutral	₹105.35B	29.90	―	0.21%	63.34%	109.89%
BIOCON	60 Neutral	₹507.42B	118.64	―	0.13%	6.80%	-75.66%
PPLPHARMA	55 Neutral	₹266.51B	271.06	―	0.07%	2.66%	-153.15%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Concord Biotech Ltd. Corporate Events

Mycophenolate Pregnancy Registry: Key Insights for Investors

The Mycophenolate Pregnancy Registry, officially titled the same, is a prospective, observational study aimed at gathering data on mycophenolate exposure during pregnancy and its outcomes. This study, sponsored by Genentech, Inc., with collaborators including Amneal Pharmaceuticals, Alkem Laboratories, Concord Biotech, and Sandoz, seeks to understand the impact of mycophenolate on pregnancy, fetal, and infant outcomes, which is crucial for evaluating the safety of mycophenolate formulations like CellCept and Myfortic.

Concord Biotech Releases Q1 2025 Financial Results

Concord Biotech Ltd. has released an investor presentation detailing its financial results for the first quarter ending June 30, 2025. This announcement is part of the company’s compliance with SEBI regulations, aiming to keep stakeholders informed about its financial performance. The presentation may impact investor perceptions and market positioning by providing insights into the company’s operational and financial health.